What is Liraglutide?
Liraglutide is a glucagon-like peptide-1 () receptor agonist that shares 97% sequence homology with endogenous human
Liraglutide — daily-acting GLP-1 agonist (Saxenda/Victoza)
In short
Acylated GLP-1 receptor agonist studied in clinical models of glucose homeostasis and body weight regulation.
Overview
Liraglutide is a glucagon-like peptide-1 () receptor agonist that shares 97% sequence homology with endogenous human
Liraglutide binds to and activates the receptor in the pancreas, gastrointestinal tract, and central nervous system. The peptide stimulates insulin secretion in a strictly glucose-dependent manner while simultaneously suppressing inappropriate glucagon release. Central receptor activation in the hypothalamus directly regulates appetite and promotes early satiety. The compound also delays gastric emptying, which blunts postprandial glucose spikes and contributes to reduced caloric intake.
Molecular information
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
SCALE Obesity (NEJM 2015, n=3731) - 3.0 mg s.c. daily for 56 weeks gave 8.0% reduction vs 2.6% placebo.
Стомашно-чревните странични ефекти, включително гадене, повръщане и диария, са много чести по време на първоначалното титриране на дозата. Пептидът носи предупреждение за потенциален риск от тумори на С-клетките на щитовидната жлеза въз основа на проучвания при гризачи. Остър панкреатит е докладван в клинични изпитвания и изисква незабавно прекратяване при съмнение. Употребата е противопоказана при пациенти с лична или фамилна анамнеза за медуларен карцином на щитовидната жлеза. Бързата загуба на тегло може да увеличи риска от холелитиаза и холецистит. Сърдечната честота може леко да се повиши по време на лечението, което изисква периодично наблюдение от медицински специалист.
4 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
SCALE Obesity
Phase 3 | 3.0 mg s.c. daily | 56 weeks | 8.0% weight loss
NEJM · 2015
View the studyInformation about Liraglutide is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadEducation
No comments yet. Be the first.
Comments are reviewed before publishing.